What are the recommended medications and dosing for gestational hypertension?

Recommended Medications for Gestational Hypertension

First-line treatment for gestational hypertension should be extended-release nifedipine or labetalol, with nifedipine often preferred due to once-daily dosing that improves adherence 1.

First-Line Antihypertensive Agents

Extended-Release Nifedipine

• Preferred initial choice due to once-daily administration 1
• Long-acting formulation for maintenance therapy
• Short-acting formulation reserved only for acute severe hypertension
• Switch to labetalol if patient experiences headaches, tachycardia, or edema 1

Labetalol

• Alternative or combination therapy when blood pressure remains uncontrolled on nifedipine alone 1
• Contraindicated in reactive airway disease 1
• Requires TID or QID dosing due to accelerated metabolism during pregnancy 1
• Minimal risks (fetal growth restriction, bradycardia, hypoglycemia) with no teratogenicity reported 1

Methyldopa

• Third first-line option with longest-term infant safety data 1
• More commonly used in low- and middle-income countries where it may be the only available agent 1
• Less well-tolerated due to side effects: peripheral edema, dry mouth, lightheadedness, drowsiness, mood effects 1
• Meta-analysis shows β-blockers and calcium channel blockers are more effective than methyldopa for preventing severe hypertension 1

Treatment Thresholds and Targets

Initiate antihypertensive therapy when blood pressure is consistently ≥140/90 mmHg 2.

Blood Pressure Goals

• Target diastolic BP: 85 mmHg 2
• Target systolic BP: 110-140 mmHg 1, 2
• Reduce or cease medications if diastolic BP falls <80 mmHg 2

Severe Hypertension (≥160/110 mmHg)

Requires urgent treatment in a monitored setting 2:

• Oral nifedipine (short-acting)
• Intravenous labetalol or hydralazine
• Oral labetalol if IV agents unavailable 2

Second-Line Agents

Use when first-line agents are contraindicated, not tolerated, or blood pressure remains uncontrolled 1:

• Hydralazine
• Prazosin 2
• Clonidine transdermal patch - particularly valuable for patients with hyperemesis 1

Critical Contraindications

Absolutely avoid:

• ACE inhibitors - contraindicated due to fetotoxicity 3
• Angiotensin II receptor blockers (ARBs) - contraindicated due to fetotoxicity 3
• Atenolol - associated with fetal growth restriction 1

Evidence Quality and Nuances

The 2025 Circulation guideline 1 represents the most current evidence and aligns with the 2018 ISSHP guidelines 2. A post-hoc analysis of the CHAP trial found no difference in maternal or neonatal outcomes between labetalol and nifedipine, though medication allocation was not randomized 1. There is no compelling data supporting one first-line agent over another 1, making the choice largely dependent on patient-specific factors like adherence capability, side effect profile, and contraindications.

Common Pitfalls to Avoid

• Do not use short-acting nifedipine for maintenance therapy - only for acute severe hypertension 1
• Do not prescribe labetalol to patients with asthma or reactive airway disease 1
• Do not continue antihypertensives if diastolic BP drops below 80 mmHg - risk of placental hypoperfusion 2
• Do not delay treatment waiting for BP to reach 160/110 - treat at 140/90 to prevent progression to severe hypertension 2